Recombinant codon optimised factor H
The present invention relates to recombinant factor H and variants and conjugates thereof and methods of their production, as well as uses and methods of treatment involving the materials.
1. A method for making a recombinant mammalian factor H (FH), the method comprising the step of:
expressing in a bacterial, fungal, insect or plant cell, in culture a codon-optimized nucleic acid sequence encoding the mammalian FH, the nucleic acid sequence comprising a deletion variant sequence of any one of SEQ ID NO: 1-13 thereof comprising domains 1-4 and 19-20 and a deletion of domains 8-18, wherein the nucleic acid sequence has been codon optimized to enhance expression in the bacterial, fungal, insect or plant cell and inserted into an expression vector.
2. The method according to claim 1 wherein at least 1 mg of the mammalian FH is produced per liter of culture medium.
3. The method according to claim 1 further comprising the step of purifying the mammalian FH from the cells and/or culture medium in which the cells are grown.
4. The method according to claim 3 , wherein purifying the mammalian FH is carried out by a chromatographic technique.
5. The method according to claim 1 , wherein the bacterial, fungal, insect or plant cell is a yeast cell, and wherein the yeast cell is Pichia pastoris.
6. The method according to claim 1 , wherein the mammalian FH is selected from the group consisting of human FH, mouse FH, rat FH, hamster FH, rabbit FH, dog FH, horse FH, cow FH, pig FH, sheep FH, camel FH, cat FH, and guinea pig FH.
7. The method according to claim 1 , wherein the codon-optimized nucleic acid sequence includes one or more single-nucleotide polymorphisms.
8. The method according to claim 7 , wherein the one or more single-nucleotide polymorphisms are selected from the group consisting of Ile62Val, Tyr402His, and Arg 1210Cys.
9. The method according to claim 1 , wherein the sequence of the mammalian FH includes one or more covalently modified natural or non-naturally encoded variant amino acids.
10. The method according to claim 9 , wherein said one or more covalently modified natural or non-naturally encoded variant amino acids is covalently modified to include a moiety selected from the group consisting of glycosaminoglycans, polysialic acids, dextran (−1,6 polyglucose), dextran (−1,4 polyglucose), hyaluronic acid, chitosans, linear or branched polyethylene glycols, polyether polyols, N-(2-hydroxypropyl) methacrylamide copolymers, poly(vinylpyrrolidone), poly(ethyleneimine), linear polyamidoamines, poly(L-lysine), poly(glutamic acid), poly(malic acid) and poly(aspartamides).
11. The method according to claim 1 , wherein the mammalian FH is conjugated with a chemical moiety or chemical moieties, wherein the moiety or moieties improve the biotherapeutic properties of the mammalian FH.
12. A nucleic acid sequence capable of expressing a FH polypeptide wherein the nucleic acid sequence is codon optimized for expression in a bacterial, fungal, insect or plant cell in culture in an amount greater than 1 mg per liter of culture wherein the nucleic acid sequence comprises domains 1-4 and 19-20 and a deletion variant sequence of any one of SEQ ID NOs: 1-13 comprising a deletion of domains 8-18.
13. A vector comprising the sequence according to claim 12 .
14. A recombinantly expressed mammalian FH expressed from the nucleic acid sequence of claim 12 .
15. A recombinantly expressed variant of mammalian FH comprising one or more amino acid residue substitutions designed to modulate one or more biological properties of the FH variant as compared to a native FH, obtained from a nucleic acid sequence capable of expressing a FH polypeptide, wherein the nucleic acid sequence is codon optimized for expression in a bacterial, fungal, insect or plant cell in culture in an amount greater than 1 mg per liter of culture and wherein the nucleic acid sequence comprises a deletion variant sequence of any one of SEQ ID NOs: 1-13 comprising domains 1-4 and 19-20, which comprises one or more amino acid substitutions and a deletion of domains 8-18.
16. A method of slowing the progression of or treating a disease in a subject in need thereof comprising the step of administering the recombinantly expressed mammalian FH according to claim 12 to the subject.
17. The method according to claim 16 for use in slowing the progression of treating a disease selected from the group consisting of AMD, atypical haemolytic uraemic syndrome (aHUS), or dense deposit disease (DDD).
18. The method according to claim 1 wherein the deletion variant comprises a deletion of domains 5-18.
19. A process for making a recombinant mammalian factor H (FH), the process comprising the step of:
expressing in Pichia pastoris a nucleic acid sequence codon optimized for enhancing expression in P. pastoris encoding the mammalian FH, wherein the nucleic acid sequence comprises a deletion variant sequence of any one of SEQ ID NOs: 1-13 comprising domains 1-4 and 19-20 and a deletion of domains 8-18.
20. The nucleic acid sequence according to claim 12 which has been codon-optimized for enhanced expression in P. pastoris.
21. The nucleic acid sequence according to claim 12 wherein the deletion variant comprises a deletion of domains 5-18.
22. The process according to claim 19 wherein the deletion variant comprises a deletion of domains 5-18.